Design, synthesis and evaluation of 6-oxo-1, 6-dihydropyrimidine-2,5-dicarboxamide derivatives as MMP 13 inhibitors

Hai-bin Lu; Shi-han Wang; Qing-min Li; Yong-sheng Wang

doi:10.1007/s40242-012-2131-2

Chemical Research in Chinese Universities ›› 2013, Vol. 29 ›› Issue (1) : 67 -70. DOI: 10.1007/s40242-012-2131-2

Article

Design, synthesis and evaluation of 6-oxo-1, 6-dihydropyrimidine-2,5-dicarboxamide derivatives as MMP 13 inhibitors

Author information +

History +

PDF

Abstract

We designed and synthsized a series of novel 6-oxo-1,6-dihydropyrimidine-2,5-dicarboxamide derivatives and evaluated their inhibition effects on MMP 3, MMP 12 and MMP 13. The pharmacological results show that they have potent and highly selective activity of inhibiting MMP 13.

Keywords

Matrix metalloproteinase 13(MMP 13) / Matrix metalloproteinase(MMP) / Inhibition

Cite this article

Download citation ▾

Hai-bin Lu, Shi-han Wang, Qing-min Li, Yong-sheng Wang. Design, synthesis and evaluation of 6-oxo-1, 6-dihydropyrimidine-2,5-dicarboxamide derivatives as MMP 13 inhibitors. Chemical Research in Chinese Universities, 2013, 29(1): 67-70 DOI:10.1007/s40242-012-2131-2

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sternlicht M. D., Werb Z. Annu. Rev. Cell Dev. Biol., 2001, 17: 463.

[2]	Liu X. C., Li H. W., Wang Y., Jiang K., Fang X. X., Wu Y. Q. Chem. J. Chinese Universities, 2010, 31(1): 88.

[3]	Shapiro S. D. Curr. Opin. Cell Biol., 1998, 10: 602.

[4]	Whittaker M., Floyd C. D., Brown P., Gearing A. J. Chem. Rev., 1999, 99: 2735.

[5]	Holleran W. M., Galardy R. E., Gao W. N., Levy D., Tang P. C., Elias P. M. Arch. Dermatol. Res., 1997, 289: 138.

[6]	Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E. Neurosci. Lett., 1995, 201: 223.

[7]	Lohmander L. S., Hoerrner L. A., Lark M. W. Arthritis Rheum., 1993, 36(2): 181.

[8]	Ahrens D., Koch A. E., Pope R. M., Stein-Picarella M., Niedbala M. J. Arthritis Rheum., 1996, 39(9): 1576.

[9]	Ohishi K., Fujita N., Morinaga Y., Tsuruo T. Clin. Exp. Metastasis, 1995, 13: 287.

[10]	Peress N., Perillo E., Zucker S. J. Neuropathol. Exp. Neurol., 1995, 54: 16.

[11]	Coussens L. M., Fingleton B., Matrisian L. M. Science, 2002, 295: 2387.

[12]	Babine R. E., Bender S. L. Chem. Rev., 1997, 97: 1359.

[13]	Hodgson J. Biotechnology, 1995, 13: 554.

[14]	Engel C. K., Pirard B., Schimanski S., Kirsch R., Habermann J., Klingler O., Schlotte V., Weithmann K. U., Wendt K. U. Chem. Biol., 2005, 12(2): 181.

[15]	Gooljarsingh L. T., Lakdawala A., Coppo F., Luo L., Fields G. B., Tummino P. J., Gontarek R. R. Protein Sci., 2008, 17(1): 66.

[16]	Barvian N. C., Patt W. C., Pyrimidine Matrix Metalloproteinase Inhibitors, US 6936616, 2005

[17]	Christian G., Carine C., Gallagher B. M. Jr., Arthur T., Metalloprotease Inhibitors Containing a Heterocyclic Moiety, WO 2008109181, 2008

[18]	Russell M. G., Carling R. W., Atack J. R., Bromidge F. A., Cook S. M., Hunt P., Isted C., Lucas M., McKernan R. M., Mitchinson A., Moore K. W., Narquizian R., Macaulay A. J., Thomas D., Thompson S. A., Wafford K. A., Castro J. L. J. Med. Chem., 2005, 48(5): 1367.